Similar articles

• Re: Greil et al.: Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals (Urology 2009;73:631-634).

  Tan WW. Tan WW. Urology. 2009 Jun;73(6):1427-8. doi: 10.1016/j.urology.2008.09.065. Urology. 2009. PMID: 19482168 No abstract available.
• Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.

  Greil S, Robinson EA, Singal B, Kleer E. Greil S, et al. Urology. 2009 Mar;73(3):631-4. doi: 10.1016/j.urology.2008.08.516. Epub 2008 Dec 24. Urology. 2009. PMID: 19110301
• [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].

  Pfitzenmaier J, Altwein JE. Pfitzenmaier J, et al. Aktuelle Urol. 2009 Mar;40(2):100-8. doi: 10.1055/s-0028-1098746. Epub 2009 Feb 27. Aktuelle Urol. 2009. PMID: 19253209 Review. German.
• Words of wisdom. Re: Adverse events associated with testosterone administration.

  Morgentaler A. Morgentaler A. Eur Urol. 2011 Mar;59(3):465. doi: 10.1016/j.eururo.2010.12.027. Eur Urol. 2011. PMID: 21414881 No abstract available.
• The effect of ketamine/xylazine and carbon dioxide on plasma luteinizing hormone releasing hormone and testosterone concentrations in the male Norway rat.

  Gould EM. Gould EM. Lab Anim. 2008 Oct;42(4):483-8. doi: 10.1258/la.2007.007090. Epub 2008 Sep 9. Lab Anim. 2008. PMID: 18782829